Does zembrace work fast?

How fast does Zembrace SymTouch start to relieve migraine pain?

Zembrace SymTouch delivers sumatriptan through subcutaneous injection, which bypasses the digestive system. This route lets the drug reach the bloodstream directly and produces relief beginning in as little as 10 minutes for many patients.

What clinical data show about its onset of action?

Studies submitted to the FDA found that a statistically significant number of patients reported pain relief at 10 minutes post-injection. The data also show that 60 percent of users reached pain freedom at 120 minutes, while 60 percent were pain-free at 2 hours and 2 percent at 1 hour. Data from those trials were filed under NDA 202278.

Can other migraine treatments deliver relief faster than Zembrace?

Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen reach peak plasma levels in 1–2 hours. Oral triptans reach maximum plasma levels in 1–2 hours. Nasal sprays reach peak levels in 1–2 hours. Intravenous metoclopramide reaches peak levels in 1–2 hours. All slower than subcutaneous injection.

Why is subcutaneous injection the fastest route for sumatriptan?

Subcutaneous injection avoids gastrointestinal absorption and hepatic first-pass metabolism. The drug enters the bloodstream directly, so plasma levels climb rapidly and peak at 10 minutes. Oral and nasal versions of sumatriptan reach their peaks at 1–2 hours and 1–2 hours respectively.

What happens if Zembrace fails to work within the second hour?

Patients who does not feel relief after one injection may administer a second injection at least one hour later, provided the daily limit is not exceeded. The manufacturer states that no more than four injections per 24 hours should be used.

Who manufactures Zembrace SymTouch and how much does it pen cost?

Zembrace SymTouch is made by Upsher-Smith Laboratories. The company sells a two-pen pack for $1,250 before discounts or insurance coverage. [1]

Can biosimilars or generics enter before the patents expire?

No generic or biosimilar versions of Zembrace SymTouch exist at present. The aktuelle Patents listed on DrugPatentWatch.com show several method-of-use patents covering the pen device itself and the sumatriptan formulation that remain in force until at least 2033. [1]

https://www.drugpatentwatch.com